A regional sales director at a medical device company noticed something odd in early 2025. One of her top hospital accounts still placed orders every month. Revenue looked flat, not falling. But the reorder intervals had quietly stretched from 21 days to 34 days, and the mix had shifted toward the cheapest SKU (stock keeping unit, a specific product variant). Six weeks later the account switched suppliers. The revenue drop showed up in Q3. The engagement drop had been visible in Q1.
That gap, between when behavior changes and when revenue changes, is what stickiness metrics exist to close. In biotech and medtech you are rarely selling a one-time purchase. You are selling into a repeated behavior: a prescriber writing a script, a surgeon choosing an implant, a lab reordering reagents. Retention is the whole game.
In consumer SaaS you track logins and clicks. In this sector the "usage" happens inside a clinical workflow you cannot see directly. So you proxy it with three families of metrics.
For consumables (reagents, catheters, test kits, injectables), the cleanest signal is whether accounts keep buying and how fast.
Reorder rate = share of accounts that placed a repeat order within a defined window.
Worked example. You sold to 400 accounts in H1 2025. By the end of H2, 300 of them reordered.
Reorder rate = 300 / 400 = 75%.
But the average hides drift. Segment it. If reorder rate among your top-quartile accounts fell from 90% to 78% while the overall number held at 75%, your best customers are leaving and new small ones are masking it.
Track the reorder interval too: the median days between orders per account. A lengthening interval is an early warning even when the account technically still "reorders."
For implants, surgical tools, and interventional devices, the metric that matters is procedure share: of all the eligible procedures a physician performs, what fraction use your product?
A cardiologist who does 40 stent cases a month and uses your stent in 12 of them gives you a 30% procedure share. If that slips to 20% next quarter, you are being designed out of cases even if raw unit volume looks stable (because their total caseload grew).
You usually cannot observe this directly. You triangulate it from your own units sold plus market data on total procedure volume in that account or territory. Providers like IQVIA sell anonymized, aggregated prescription and procedure datasets used for exactly this. Compliance note: this data is aggregated and privacy-controlled under laws like HIPAA (the US Health Insurance Portability and Accountability Act) and GDPR (the EU General Data Protection Regulation). You are analyzing patterns, not individual patients.
A formulary is the list of drugs a payer or hospital will reimburse or stock. Getting on it is acquisition. Staying on it, at a favorable tier (position that sets the patient's copay; lower tiers mean cheaper for the patient and more prescribing), is retention.
Formulary persistence tracks whether you hold your formulary positions across review cycles and whether prescribing continues once you are listed. Two related drug-specific metrics:
If NBRx is strong but 6-month persistence is weak, you have a leaky bucket: you win starts and lose them before the revenue compounds.
The point of these metrics is not to admire them. It is to flag accounts drifting *before* revenue falls. A simple, practical approach: build an account health score from directional changes, not absolute levels.
# Simple account drift flag (illustrative)
def drift_flag(reorder_interval_change, procedure_share_change, sku_mix_shift):
score = 0
if reorder_interval_change > 0.15: # interval stretched >15%
score += 2
if procedure_share_change < -0.10: # lost >10 pts of share
score += 3
if sku_mix_shift == "down": # trading to cheaper SKU
score += 1
return "AT RISK" if score >= 3 else "OK"This is deliberately crude. The lesson is the logic: weight *changes* in behavior, watch the fastest-moving accounts, and act while the account is still buying.
Benchmarks in this sector are messy because product categories differ wildly. Treat every number below as an approximate, commonly cited estimate as of early-to-mid 2025, not a precise figure, and always re-anchor to your own baseline.
Do not import a SaaS churn benchmark and apply it to an orthopedic implant line. The buying cycle, the switching cost, and the regulatory friction are all different.
🎬 [VIDEO: "Customer Retention & Cohort AnalysisCohort AnalysisCohort analysis groups users by a shared starting trait or time (such as signup month) and tracks their behavior over time to reveal retention and lifecycle patterns.View full definition → Explained" - youtube.com - a clear, sector-neutral primer on cohort retention curves you can mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → onto reorder and persistence data]
Average retention lies. Cohort analysisCohort analysisCohort analysis groups users by a shared starting trait or time (such as signup month) and tracks their behavior over time to reveal retention and lifecycle patterns.View full definition → does not. Group accounts (or patients) by when they started, then track each group's survival over time.
Example. Take every account acquired in Q1 2025 and measure what fraction is still ordering at month 3, 6, 9, 12. Do the same for Q2, Q3. If each newer cohort retains worse at month 6, your acquisition quality is degrading, maybe you are winning price-sensitive accounts that never intended to stay. Blended averages would hide this for a year.
The same technique works for drug persistence: cohort patients by start month, plot the survival curve, and compare against your therapy's benchmark range.
Knowledge check
1. Why do stickiness metrics like reorder interval matter for early detection of account risk in medtech/biotech?
2. An account still reorders every month and its total revenue is flat, but the median days between orders has grown and purchases have shifted to the cheapest SKU. What is the best interpretation?
3. Why is measuring engagement in this sector fundamentally different from consumer SaaS?
4. Select ALL correct answers about why segmenting reorder rate is more informative than an aggregate figure.
Select all the correct answers.
5. Select ALL correct answers about the reorder interval as an engagement metric.
Select all the correct answers.
Retention metrics feed Customer Lifetime Value (CLV), the total margin an account or patient generates over its lifetime. In this sector CLVCLVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → is unusually powerful because relationships are long and switching costs are high, but only if retention holds.
A simplified worked example for a consumables account:
CLVCLVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → = $50,000 / 0.15 = about $333,000.
Now watch the sensitivity. Push retention from 85% to 90% (churn 10%):
CLVCLVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → = $50,000 / 0.10 = $500,000.
A 5-point retention improvement raised modeled lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → by roughly 50%. That is why spotting drift early is worth more than winning new logos. (This formula ignores discounting and margin growth; use it for intuition, not for your finance filings.)
The same logic reframes the metrics above:
Each one is a lever on the same CLVCLVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → equation.
The workflow for a medtech or biotech marketing team:
1. Pick the right stickiness metric per product type (reorder for consumables, procedure share for devices, formulary persistence and patient persistence for drugs).
2. Track changes and intervals, not just levels, and segment by account tier.
3. Build cohorts so averages cannot hide degradation.
4. Convert retention into CLVCLVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → so the whole organization sees why early drift signals matter in dollars.